loading page

Filgrastim Desensitization in a Patient with Hodgkin Lymphoma
  • +2
  • Hannah Jeter,
  • Kathleen Grisanti,
  • Amelia Jantz,
  • Aman Wadhwa,
  • Emily Waite
Hannah Jeter
Auburn University - Harrison School of Pharmacy
Author Profile
Kathleen Grisanti
The University of Alabama at Birmingham Department of Pediatrics
Author Profile
Amelia Jantz
The University of Alabama at Birmingham Department of Pediatrics
Author Profile
Aman Wadhwa
The University of Alabama at Birmingham Department of Pediatrics
Author Profile
Emily Waite
The University of Alabama at Birmingham Department of Pediatrics

Corresponding Author:[email protected]

Author Profile

Abstract

Filgrastim is a granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, and is used to prevent or treat febrile neutropenia in patients undergoing chemotherapy. Hypersensitivity reactions (HSRs) to G-CSF formulations, such as filgrastim, pegfilgrastim and biosimilars are rare, and few reports exist regarding desensitization protocols, particularly in the pediatric population. In this brief report, we describe successful desensitization and subsequent use of G-CSF (biosimilar product Nivestym®) in an adolescent with Hodgkin lymphoma who experienced anaphylaxis after her first dose.